pillbase.ru

ARANESP

Active substance: darbepoetin alfa

INJECTION, SOLUTION · DARBEPOETIN ALFA 300 ug/.6mL

United StatesActive

Marketing holder: Amgen, Inc

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
EU 2
  • Aranesp
    darbepoetin alfa
    EMEA/H/C/000332
    Amgen Europe B.V.
  • Nespo
    darbepoetin alfa
    EMEA/H/C/000333
    Dompé Biotec S.p.A.
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208c-782a-7d47-8db4-37f4d0cf72c9,01a1208d-4541-7ad9-b658-3ead052b97fc,01a1208d-4545-74ab-9650-476b6cfa1c93,01a1208e-7a06-7d5e-a0c7-0247062b97f7,01a1208e-7a10-79fa-b27f-0b690725a242;count=14 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
55513-111
Registration status
Active
Dispensing
Prescription only
Route
INTRAVENOUS, SUBCUTANEOUS
Sources
  • product · openFDA NDC · 55513-111 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 55513-111 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 55513-111 · Verified 2026-10-09 · open in source